Early Surveillance with L-Dex® Reduces Incidence, Severity & Cost of Breast Cancer-Related Lymphedema, ImpediMed Reports Publication in American Cancer Society Journal

BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)-- ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced the publication of a landmark study from the prominent research institute Macquarie University. The study found that the use of BIS as part of an early prospective surveillance model of care results in significantly earlier detection of lymphedema over time, which can lead to lower healthcare costs.

Conducted by Louise Koelmeyer, Lymphoedema Program Manager, Australian Lymphoedema Education, Research & Treatment (ALERT), the study was published in CANCER, the official biweekly, peer-reviewed scientific journal of the American Cancer Society.

“My vision is that all women diagnosed with breast cancer will have access to a prospective surveillance model of care which includes BIS technology, education and early intervention,” says Koelmeyer.

This large retrospective analysis of a busy practice study examined the outcomes of patients who were followed in either an early surveillance group or a traditional referral group. The early surveillance group included patients prospectively followed with L-Dex, from a pre-operative baseline or within 90 days of surgery. The traditional referral group consists of patients who were referred to the practice > 90 days from the time of surgery.

The results indicate that women who underwent early surveillance received lymphedema care almost two years earlier than women in the traditional referral group. The early surveillance group had a significantly lower incidence of clinical lymphedema than the traditional referral group, and those who were diagnosed in the early surveillance group had significantly less severe lymphedema.

Richard Carreon, managing director and CEO, ImpediMed, points to the significance of this study, stating, “This is an important piece of work demonstrating the long-term value of a prospective model of care using ImpediMed’s L-Dex technology to improve patient outcomes and reduce the cost of care. This landmark study adds to the growing body of clinical evidence and will significantly strengthen our presentations to the National Comprehensive Cancer Network (NCCN) and discussions with private payers.”

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO^® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005080/en/